Health Care Decision Makers’ Use of Comparative Effectiveness Research: Report from a Series of Focus Groups

2013 ◽  
Vol 19 (9) ◽  
pp. 745-754 ◽  
Author(s):  
Lorenzo Villa ◽  
Terri L. Warholak ◽  
Lisa E. Hines ◽  
Ann M. Taylor ◽  
Mary Brown ◽  
...  
2005 ◽  
Vol 165 (16) ◽  
pp. 1917 ◽  
Author(s):  
Paul R. Billings ◽  
Rick J. Carlson ◽  
Josh Carlson ◽  
Mary Cain ◽  
Charles Wilson ◽  
...  

Surgery ◽  
2020 ◽  
Vol 167 (2) ◽  
pp. 396-403 ◽  
Author(s):  
Brooks V. Udelsman ◽  
Nicolas Govea ◽  
Zara Cooper ◽  
David C. Chang ◽  
Angela Bader ◽  
...  

2012 ◽  
Vol 30 (34) ◽  
pp. 4194-4201 ◽  
Author(s):  
Olwen M. Hahn ◽  
Richard L. Schilsky

Comparative effectiveness research (CER) has been promoted as a way to improve the translation gap between clinical research and everyday clinical practice as well as to deliver more cost-effective health care. CER will account for a significant portion of funding allocated by the US government for health care research. Oncology has a rich history of improving clinical outcomes and advancing research through randomized controlled trials (RCTs). In this article, we review the role of RCTs in achieving the goals of CER, with particular emphasis on the role of publicly funded clinical trials.


Sign in / Sign up

Export Citation Format

Share Document